-
Taxonomy & unit
-
ratio: %
-
Description
-
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
-
Summary
-
Aerovate Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2022 to Q3 2025.
- Aerovate Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2025 was 66.9 %, a 98.5% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)